| Date | Form | Description | Docs | XBRL | Pages |
| 09/29/10 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
3 | |
| 09/28/10 | UPLOAD | SEC-generated letter |
|
2 | |
| 09/27/10 | DEF 14A | Definitive proxy statements |
|
21 | |
| 09/14/10 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
58 | |
| 09/14/10 | 10-Q/A | Quarterly report pursuant to sections 13 or 15(d) |
|
14 | |
| 08/24/10 | 3 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 08/20/10 | 8-K | Current report filing |
|
3 | |
| 07/27/10 | CT ORDER | Confidential treatment order |
|
1 | |
| 07/27/10 | UPLOAD | SEC-generated letter |
|
1 | |
| 07/21/10 | SC 13D/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
11 |
Latest News & Events
Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic
Read More...Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
Read More...Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025
Read More...